Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.69 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.69 |
| ▸ | BRAF | P15056 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529782 | 1.00 | MAP2K1 (0.69) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24195789 | 0.88 | MAP2K1 (0.64) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24195673 | 0.88 | MAP2K1 (0.64) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24195672 | 0.88 | MAP2K1 (0.64) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL4860874 | 0.83 | MAP2K1 (0.73) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL13119544 | 0.83 | MAP2K1 (0.65) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL4854513 | 0.83 | MAP2K1 (0.73) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| Mirdametinib SCHEMBL29358470 | 0.82 | MAP2K1 (1.00) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| Mirdametinib SCHEMBL895854 | 0.82 | MAP2K1 (1.00) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| Mirdametinib SCHEMBL172904 | 0.82 | MAP2K1 (1.00) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256149-A1 | NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | US | claimed |
| US-20070287709-A1 | Novel arylamino N-heteraryls as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | claimed |
| US-8802703-B2 | Arylamino N-heteraryl compounds as MEK inhibitors | MERCK SERONO S.A. (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802703-B2 | Arylamino N-heteraryl compounds as MEK inhibitors | MERCK SERONO S.A. (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802703-B2 | Arylamino N-heteraryl compounds as MEK inhibitors | MERCK SERONO S.A. (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20100256149-A1 | NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | US | disclosed |
| US-20100256149-A1 | NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | US | disclosed |
| US-20100256149-A1 | NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | US | disclosed |
| US-7772233-B2 | Arylamino N-heteroaryl compounds as MEK inhibitors | Merck Serono, S.A. (CH) | 2010-08-10 | — | — | US | disclosed |
| US-7772233-B2 | Arylamino N-heteroaryl compounds as MEK inhibitors | Merck Serono, S.A. (CH) | 2010-08-10 | — | — | US | disclosed |
| US-7772233-B2 | Arylamino N-heteroaryl compounds as MEK inhibitors | Merck Serono, S.A. (CH) | 2010-08-10 | — | — | US | disclosed |
| US-20070287709-A1 | Novel arylamino N-heteraryls as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287709-A1 | Novel arylamino N-heteraryls as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287709-A1 | Novel arylamino N-heteraryls as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| WO-2007123939-A2 | NOVEL ARYLAMINO N-HETERARYLS AS MEK INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256149-A1 | NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS | NRAS, MAP3K19, MAP3K20 | MAP2K1 50/4885MAP2K2 42/4885BRAF 5/4885 |
| US-20070287709-A1 | Novel arylamino N-heteraryls as MEK inhibitors | NRAS, MAP3K19, MAP3K1 | MAP2K1 48/4885MAP2K2 39/4885BRAF 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.